A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Schizophrenia in Adolescents (EMERGENT TEEN) (NCT07288567)
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Schizophrenia in Adolescents (13 to 17 Years of Age)
🩺 Plain-English Summary (8th-Grade Level)
The purpose of this study is to evaluate the efficacy and safety of KarXT for treatment of Schizophrenia in adolescents.
Who can join: Review the eligibility criteria below.
Location: Advanced Research Center Inc. — Anaheim, California
Age range: 13 Years to 17 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (39 Sites)
Showing the first 25 of 39 sites.
- Advanced Research Center Inc. — Anaheim, California
- Inland Psychiatric Medical Group. — Chino, California
- Proscience Research Group — Culver City, California
- Local Institution - 0089 — San Francisco, California
- Local Institution - 0119 — Hollywood, Florida
- Apg Research, Llc — Orlando, Florida
- Atlanta Center for Medical Research — Atlanta, Georgia
- Salveo Integrative Health - Lawrenceville — Lawrenceville, Georgia
- Denali Health Atlanta, LLC — Stone Mountain, Georgia
- Local Institution - 0122 — Chicago, Illinois
- EmVenio Research Center - Prime Healthcare — Chicago, Illinois
- Boston Children's Hospital — Boston, Massachusetts
- Local Institution - 0059 — Worcester, Massachusetts
- Local Institution - 0061 — Great Neck, New York
- University of Cincinnati Dept of Psychiatry and Behavioral Neuroscience — Cincinnati, Ohio
- Local Institution - 0113 — Nashville, Tennessee
- VAST Clinical Research — Garland, Texas
- Local Institution - 0120 — Houston, Texas
- Local Institution - 0118 — Plano, Texas
- Local Institution - 0066 — Spring, Texas
- Local Institution - 0050 — Richmond, Virginia
- Local Institution - 0109 — Bello, Antioquia
- Local Institution - 0009 — Pereira, Risaralda Department
- Local Institution - 0001 — Barranquilla,
- Local Institution - 0020 — Bogotá,
📞 Contact the Study Coordinator
Phone: (855) 907-3286
Email: Clinical.Trials@bms.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Schizophrenia
- Young Adults With Violent Behavior During Early Psychosis (Aim 2) — New York, New York
- Does tDCS Change Synaptic Density in the Brains of Patients With Schizophrenia — Toronto, Ontario
- Ketogenic Diet in People With Schizophrenia — Catonsville, Maryland
- Paired Associative Stimulation in the Dorsolateral Prefrontal Cortex in Patients With Schizophrenia — Toronto, Ontario
- Investigating the Muscarinic System in Schizophrenia Using Positron Emission Tomography — Toronto, Ontario
- Long-Term Real-World Safety of Cobenfy in Adults With Schizophrenia — Suwanee, Georgia
Explore by condition: All Schizophrenia clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.